Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TR004 in Crohn's Disease
NCT03185000Phase 1Unknown
- Sponsor
- King's College London
- Start
- Aug 2022
- Primary completion
- Mar 2024
- Modality
- Prophylactic Vaccines, Regulatory T Cells (Tregs), Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of TR004 in Crohn's disease, sponsored by King's College London. Primary endpoint: Dose-Limiting Toxicities at 5 weeks. Status: unknown.
02
Drugs
TR004
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03185000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03185000.